Program
rovatirelin
Also written as “KPS-0373”, “KPS-0373, High dose” and “KPS-0373, Low dose”.
Its studies are mostly in Spinocerebellar Degenerations, led by Kissei Pharmaceutical.
Furthest: phase 3, since Oct 22, 20139 company-led studies, 1 open or runningNext primary completion: Mar 31, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kissei Pharmaceutical | 91 open or running | phase 3since Oct 22, 2013 | Mar 16, 2009 | Mar 31, 2027phase 3 · NCT07040137 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 16, 2009First study: phase 2 study in Spinocerebellar DegenerationsFirst studyNCT00863538 · 40 enrolled · Japan
- Oct 27, 2009Phase 2 study in Spinocerebellar DegenerationsNCT01004016 · 20 enrolled · Japan
- Jun 23, 2011Phase 2 study in Spinocerebellar DegenerationsNCT01384435 · 200 enrolled · Japan
- Oct 22, 20134 phase 3 studies in Spinocerebellar DegenerationsNCT01970137, NCT01970124, NCT01970111 and 1 more
- Aug 31, 2016Phase 3 study in Spinocerebellar DegenerationsNCT02889302 · 203 enrolled · Japan
- Jun 25, 2025Phase 3 study in Spinocerebellar DegenerationsNCT07040137 · 142 enrolled · Japan
Ahead
- Mar 31, 2027Primary completion: phase 3 study in Spinocerebellar DegenerationsNCT07040137
TargetBeta
TRHR →read by rule
“Thyrotropin-releasing hormone receptor agonist”ChEMBL 37, by rule
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07040137Spinocerebellar Degenerations · Japan | 3 | Active, not recruiting | Mar 31, 2027 | 142 |
| NCT02889302Spinocerebellar Degenerations · Japan | 3 | Completed | Mar 2018 | 203 |
| NCT01970137Spinocerebellar Degenerations · Japan | 3 | Completed | Oct 2014 | |
| NCT01970124Spinocerebellar Degenerations · Japan | 3 | Completed | May 2015 | |
| NCT01970111Spinocerebellar Degenerations · Japan | 3 | Completed | Jul 2015 | |
| NCT01970098Spinocerebellar Degenerations · Japan | 3 | Completed | Jan 2015 | 374 |
| NCT01384435Spinocerebellar Degenerations · Japan | 2 | Completed | 200 | |
| NCT01004016Spinocerebellar Degenerations · Japan | 2 | Completed | 20 | |
| NCT00863538Spinocerebellar Degenerations · Japan | 2 | Completed | 40 |
How it is read
Names in the registry
- “KPS-0373”, 8 entries
- “KPS-0373, High dose”, 4 entries
- “KPS-0373, Low dose”, 4 entries
Conditions, from the studies’ own filings
- Spinocerebellar Degenerations, 9 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.